Scientific strategy · Business development
Scientific strategy and business development for biopharma.
I help biopharma and digital health leaders compare assets, choose where to invest time and budget, and build partnership cases that answer the questions pharmaceutical buyers ask.
Berlin-based · International engagements · Selected independent advisory
Dr. Dennis Kwiatkowski
Biochemist · Strategist · Business development advisor
- oncology assets screened
- 1,200+
- pharma engagements led
- Multiple six-figure
- biochemistry and protein science
- PhD
- scientific and commercial experience
- Research → market
Selected experience
A dated snapshot of my core research, consulting and commercial roles. Additional collaborations and ventures are detailed on the About and Ventures pages.
01
2024–presentTemedica
Pharma partnerships · RWE and digital health
02
2021–2024Scitaris
Biotech and pharma strategy consulting
03
2015–2020Charité and Freie Universität Berlin
Doctoral research · biochemistry and biophysics
04
Before 2015Bayer HealthCare
Industry structural-biology research
Core engagements
Three defined service areas.
Typical scopes define the business question, required analysis, stakeholders, and timeline.
01
Technology and Opportunity Assessment
Compare the scientific rationale, clinical data, competitive position, and commercial potential before you build, partner, license, or invest.
02
Pharma Partnership Strategy
Identify the right buyers, sharpen the value proposition, and design a pilot that answers medical, commercial, and procurement questions.
03
Fractional Business Development and Advisory
Add part-time senior capacity for account selection, partner outreach, pipeline reviews, and deal preparation.
Selected outcomes
Representative work in licensing, portfolio strategy, and pharma partnerships.
The summaries cover project scale, role, work product, and outcome. Client and asset details remain confidential.
Business development and licensing
1,200+ assets · 2022
Oncology asset screen for an in-licensing pipeline
An asset screen for a confidential EU biotech moved from database review to prioritization, deep dives, and due diligence.
Read this case studyPortfolio strategy
2 engagements · 2023
Radiopharmaceutical portfolio assessment and prioritization
Every clinical and preclinical program in scope was assessed systematically for a confidential US radiopharma biotech.
Read this case studyDigital health and real-world evidence
Multiple six-figure deals
Pharma data and digital health account development
As sole account owner, I led opportunities with German affiliates of multinational pharmaceutical companies from account plan to contracted scope.
Read this case studyVentures and advisory roles
Building and advising beyond client projects.
I also work on ventures in life sciences, digital health and cross-border business. These activities inform how I assess products, customers and execution risk.
Explore ventures and investmentsFounder and investor
Berlin Sofia Partners
Selected technology and healthcare investments.
Platform operator
StartinBG
Information for cross-border founders evaluating Bulgaria.
Founder
acneinversa.life
Evidence-informed patient education for hidradenitis suppurativa.
Independent advisor
Orbion
Commercial positioning for life-sciences AI workflows.
Working model
How I structure an engagement.
01
Frame
Define the scope, constraints, stakeholders, and success criteria.
02
Compare
Apply consistent scientific, clinical, competitive, and commercial criteria.
03
Recommend
Summarize the strongest options, trade-offs, and unresolved risks.
04
Support
Prepare partner materials, account plans, or the next workstream.
Background
Biochemistry PhD with consulting and commercial experience.
I combine a doctorate in biochemistry with hands-on experience in asset screening, portfolio comparison, pharma partnerships, digital health, and six-figure account ownership.
Read about my experience“I can confidently say he is one of the most dedicated and skilled consultants I’ve worked with. Dennis has a strong scientific mindset, and his analytical skills are exceptional; he has a knack for digging deep into data and uncovering insights that others might miss.”
“Dennis is an excellent sparring partner when digital health startups and pharmaceutical companies need to find common ground. He makes complex topics tangible and shares practical experience openly.”
Selected engagements